Shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) saw unusually-strong trading volume on Thursday . Approximately 3,113,031 shares were traded during trading, an increase of 217% from the previous session’s volume of 980,822 shares.The stock last traded at $7.64 and had previously closed at $6.90.

Several analysts have recently weighed in on RPTP shares. Zacks Investment Research downgraded Raptor Pharmaceutical Corp. from a “hold” rating to a “sell” rating in a research report on Tuesday, May 3rd. Wedbush reiterated a “neutral” rating and set a $4.00 target price on shares of Raptor Pharmaceutical Corp. in a research report on Friday, May 6th. FBR & Co reiterated a “hold” rating on shares of Raptor Pharmaceutical Corp. in a research report on Sunday, June 12th. Finally, Citigroup Inc. downgraded Raptor Pharmaceutical Corp. from a “buy” rating to a “neutral” rating and lifted their target price for the stock from $6.00 to $8.00 in a research report on Monday, August 8th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $7.21.

The stock’s market cap is $638.94 million. The company’s 50-day moving average is $6.16 and its 200 day moving average is $5.06.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last issued its earnings results on Thursday, August 4th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.02. The company earned $32.05 million during the quarter, compared to analysts’ expectations of $28.52 million. During the same quarter in the previous year, the company earned ($0.17) earnings per share. The firm’s quarterly revenue was up 37.4% compared to the same quarter last year. Equities research analysts forecast that Raptor Pharmaceutical Corp. will post ($0.90) EPS for the current year.

A hedge fund recently raised its stake in Raptor Pharmaceutical Corp. stock. Cornerstone Capital Management Holdings LLC. increased its stake in shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) by 319.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 251,803 shares of the company’s stock after buying an additional 191,703 shares during the period. Cornerstone Capital Management Holdings LLC. owned approximately 0.30% of Raptor Pharmaceutical Corp. worth $1,310,000 at the end of the most recent quarter.

Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.